Ionis Cuts Key Drug Revenue Outlook by 50%; Shares Fall 19%
Ionis Pharmaceuticals cut revenue guidance for a key therapy due to sluggish sales. Shares fell 19% to $32.09 in premarket trading Monday.
By Mariapaula GonzalezIonis Pharmaceuticals stock tumbled in premarket trading Monday after the drugmaker slashed revenue guidance for a key therapy due to sluggish sales.Shares of the biotech slumped 19% to $32.09 in premarket trading Monday. The stock was heading for its worst single-day percenta…